Altimmune to Announce Third Quarter 2021 Financial Results on November 10, 2021

November 3, 2021 at 4:01 PM EDT

GAITHERSBURG, Md., Nov. 03, 2021 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will report its third quarter 2021 financial results on Wednesday, November 10, 2021.

Altimmune management will host a conference call for investors beginning at 8:30 am E.T. to discuss the third quarter 2021 financial results and provide a business update.

Conference Call Information:

Date: Wednesday, November 10
Time: 8:30 am Eastern Time
Domestic Dial-in: (844) 615-6509
International Dial-in: (918) 922-3148
Conference ID: 5783655

About Altimmune
Altimmune is a clinical stage biopharmaceutical company focused on developing treatments for obesity and liver diseases. Our pipeline includes next generation peptide therapeutics for obesity, NASH (ALT-801), and chronic hepatitis B (HepTcell™). For more information on Altimmune, please visit

Follow @Altimmune, Inc. on LinkedIn
Follow @AltimmuneInc on Twitter

Investor and Media Contact:
Will Brown
Chief Financial Officer
Phone: 240-654-1450


Primary Logo

Source: Altimmune, Inc


Investor Contact

Will Brown
Chief Financial Officer



Email Alerts

Automatically receive Altimmune, Inc. financial information by e-mail